Chen X, Chen Z, Azman AS, et al. - Considering the necessity for a systematic landscape of neutralizing antibodies against emerging SARS-CoV-2 variants, researchers herein systematically searched for studies examining neutralizing antibodies titers induced by previous infection or vaccination against SARS-CoV-2 variants and gathered individual data. Per findings from 106 identified studies meeting the eligibility criteria, natural-infection-mediated neutralization was significantly escaped by lineage B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta), while there was slight decrease in neutralizing titers against B.1.1.7. Serum from vaccinees also resulted in significant decreases in neutralization of B.1.351 across various platforms, with an average of 7.1-fold (5.5-9.0) for non-replicating vector platform, 4.1-fold (3.7-4.4) for mRNA platform, and 2.5-fold (1.7-2.9) for protein subunit platform. mRNA vaccines induced neutralizing antibodies levels against SARS-CoV-2 variants which were comparable, or higher, than that derived from naturally-infected individuals.